Endonovo Therapeutics (OTCQB: ENDVD), a commercial-stage developer of noninvasive Electroceutical(R) therapeutic devices, today announced the delivery of SofPulse(R) evaluation units to all thirty-two National Football League (“NFL”) teams. “With injuries affecting the NFL more than any other professional sports league, we are pleased to support the health of NFL players by providing SofPulse(R) evaluation units to all NFL teams,” Endonovo Therapeutics CEO Alan Collier said in the news release. “The SofPulse(R) device is clinically proven to reduce post-operative pain, swelling and need for opioids. Endonovo is committed to helping NFL players get back on the field faster when recovering from medical procedures caused by injuries. We are currently expanding our sales and marketing efforts to other leagues and all levels, from high school to professional athletes.”
To view the full press release, visit http://nnw.fm/lO0Yl
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals(R) therapeutic devices. The Company’s current portfolio of commercial and clinical-stage wearable Electroceuticals(R) therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (“CNS”) Disorders, including traumatic brain injury (“TBI”), acute concussions, post- concussion syndrome and multiple sclerosis. The Company’s non-invasive Electroceutical(R) therapeutic device, SofPulse(R), using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company’s current portfolio of pre-clinical stage Electroceuticals(R) therapeutic devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (“NASH”), cardiovascular and peripheral artery disease (“PAD”), and ischemic stroke. The Company’s non-invasive, wearable Electroceuticals(R) therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur. For more information, visit the company’s website at www.Endonovo.com.
NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://nnw.fm/ENDV
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
Office
[email protected]
NetworkNewsWire is part of the InvestorBrandNetwork.